Review Article
Design and Optimization of the Circulatory Cell-Driven Drug Delivery Platform
Table 3
Different cells loaded with varied cargos for cancer diagnosis and therapy.
| | Refs. | Cell type | Loading method | Drugs/NPs | Drug/NP size (nm) | Cancer type | In vivo/in vitro |
| | [36] | NE | Encaps. | PTX/liposome NPs | 100 | Glioblastoma | In vitro | | [38] | NE | Encaps. | BSA/PTX NPs | 130 | Gastric cancer | In vivo | | [55] | NE | Injecting and engulfed by NE in vivo | BSA/PLGA NPs | 450 | Prostate cancer | In vivo | | [12] | T cell | BP | SN-38/liposome NPs | 340 | Lymphoma | In vivo | | [43] | T cell | BP | siRNA/liposome NPs | 150 | N/A | In vitro | | [59] | T cell | BP | NSC-87877/liposome NPs | 200 | Prostate cancer | In vivo | | [51] | T cell | BP | IL-15Sa/nanogel | 121 | Melanoma | In vivo | | [54] | T cell | BP | Liposome NPs | 100/200/300 | Lymphoma/lung cancer | In vivo | | [56] | T cell | Injecting and hitchhiking T cell in vivo | Curcumin/aPD1/PEG NPs | 43-50 | Melanoma | In vivo | | [65] | T cell | Encaps. | AuNPs | 45 | Lymphoma | In vivo | | [70] | T cell | Encaps. | Dox/TargetMAG NPs | 50 | N/A | In vitro | | [17] | NK | BP | PTX/liposome NPs | 220 | Ovarian cancer | In vivo | | [42] | NK | BP | TRAIL/anti-CD57/liposome NPs | 161 | Prostate/breast/colon cancer | In vitro | | [57] | NK | Injecting and hitchhiking NK in vivo | Trail/anti-NK1.1/liposome NPs | 138 | Melanoma, colon cancer | In vivo | | [18] | MA | Encaps. | Dox/SiO2 NPs | 28.4 | Glioblastoma | In vivo | | [25] | MA | Encaps. | Au/BSA nanorods | 7 | Liver cancer | In vivo | | [30] | MA | Encaps. | Dox/liposome NPs | 150 | Lung cancer | In vivo | | [47] | MA | BP | Fluorophores | N/A | Breast cancer | In vivo | | [64] | MA | Encaps. | Dox/PLGA NPs | 141.6 | Glioblastoma | In vivo | | [67] | MA | Encaps. | AuNRs & Dox/liposome NPs | 145 | Breast cancer | In vivo | | [68] | MA | Encaps. | Dox only | N/A | Breast cancer | In vivo | | [71] | MA | Encaps. | PTX/Fe3O4/liposome NPs | 110.36 | Breast/colon cancer | In vitro | | [73] | MA | Encaps. | SN-38 NPs | 119.13 | Lung/breast cancer | In vivo | | [44] | MO | Encaps. | Polystyrene microbeads | 100/300/1000 | N/A | In vitro | | [45] | MO | Encaps. | RGD/cy5.5/PEG-SWNT | 0.8-1.2 | Glioblastoma | In vivo | | [49] | MO | BP | LbL disk (500 nm thick) | 7000 | Inflamed lung | In vivo | | [72] | MO | Encaps. | Dox/poly(AAc-co-DSA) NPs | 200-260 | Prostate cancer | In vivo | | [6] | NSC | BP | Docetaxel/PEG-PDPAEMA NPs | 400 | Breast cancer | In vivo | | [19] | MSC | Bioengineered | Fluorescence | N/A | Liver/lung cancer | In vivo | | [40] | MSC | Encaps. | Quantum dots/PEG NPs | 14.5 | Breast cancer | In vivo | | [41] | MSC | Bioengineered | IFN-α | N/A | Melanoma | In vivo | | [52] | MSC | BP | Dox/silica nanorattle | 152.9 | Glioblastoma | In vitro | | [53] | MSC | BP | Curcumin/chitosan NPs | 377 | Lung cancer | In vivo | | [58] | MSC | BP | FluoSpheres | 40 | Liver cancer | In vitro | | [69] | MSC | Encaps. | PTX/PLGA NPs | 135.3 | Glioblastoma | In vivo | | [74] | MSC | Encaps. | PTX/PLGA/TAT NPs | 225 | Lung cancer | In vivo | | [23] | RBC | Encaps. | ICG-BSA NPs & free Dox | N/A | Glioblastoma | In vitro | | [24] | RBC | BP | Ferritin/ZnF16Pc NPs | 15-18 | Glioblastoma | In vivo | | [46] | RBC | Both | Free Dox (in), Ce6 (on membrane) | N/A | Breast cancer | In vitro | | [48] | RBC | Both | ICG/BSA (in), upconversion NPs (on membrane) | 40 | Liver cancer | In vivo | | [61] | RBC | BP | PS or LDNG NPs | 171/268 | N/A | In vitro |
|
|
Encaps. = encapsulation; BP = backpack. For other abbreviations, please refer to the abbreviation list.
|
